Logo

Integrating Target-based and Phenotypic Screening Strategies with Human Cardiomyocytes

Blake Anson, PhD
Tuesday, March 31, 2015
Tweet
Transcript Embed
  • Email
  • Bookmark
  • <<
  • <
  • >
  • >>

Tweet
Facebook
  • Email

Chapters

  • Introduction
  • Outline
  • iPS Cell Technology: Access to Relevant Human Biology
  • iPS Cell Technology: Revolutionary Access to Human Biology
  • Company Overview
  • Product Portfolio
  • Standardization: Manufacturing Benchmarks
  • iCell Tissue Cells
  • MyCell Products: Donor Samples, CDI Technology
  • Enabling Use: Assays, Platforms, and Protocols
  • Rigorous Characterization: iCell Cardiomyocytes
  • iCell Neurons: Alzheimer’s Disease Model - Aβ Induced Toxicity
  • Cardiac Hypertrophy: Native Phenotype
  • Cardiac Hypertrophy: Induction in iCell Cardiomyocytes
  • iCell Cardiomyocytes: Hypertrophy Screening Assay Validation
  • MyCell Cardiomyocytes: Innate disease models
  • The Power of IPSC Technology
  • Case study #6: Innate disease models: Population and disease diversity
 

No transcript for this webinar

More InformationRequest info